Evaluating the Cutaneous Pharmacokinetics of Topical Drug Products Using Pharmacokinetic Tomography (U01 Clinical Trial Required)
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The Food and Drug Administration, under the Department of Health and Human Services, is seeking to fund the research and development of non-invasive technologies to characterize how topically applied drugs reach the skin in vivo. This initiative focuses on creating quantitative tomography-based apparatus, study designs, and data analysis methods to accurately measure drug concentrations at various skin depths. The goal is to establish a sensitive and reproducible approach for monitoring cutaneous pharmacokinetics through repeated serial measurements. Ultimately, this project aims to develop a scientifically valid, in vivo pharmacokinetic approach that serves as an efficient alternative for demonstrating the bioequivalence of topical products. This forecast, categorized under NAICS code 541715, requires a clinical trial and is managed by the FDA to advance the capabilities of monitoring drug availability at or near the site of action within the skin.
General Info
Agency
Place of Performance
Not specifiedSet-Aside
Documents
0AI Contract Breakdown
Uniform Contract FormatNo documents to break down
The breakdown needs solicitation documents. None were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
The purpose of this funding opportunity is to support the research and development necessary to advance non-invasive (e.g., quantitative tomography-based) technologies, including the development of apparatus, methods, study designs, and methods of data analysis, to characterize and compare the rate and extent to which a topically applied drug becomes available at or near a site of action within the skin in vivo. The expectation is that the funded work will produce an accurate, sensitive and reproducible approach that rapidly measures the (relative) amount of drug present in the skin at a series of depths below the skin surface, which can be utilized to monitor the cutaneous pharmacokinetics (PK) of the drug at selected depths (e.g., in the epidermis) by repeated, serial measurements over time. The intent is to support the eventual development of an alternative, scientifically valid, in vivo cutaneous PK-based approach that can be used to efficiently demonstrate the bioequivalence (BE) of topical products.
Similar Contracts
Same NAICS industry code
Ready to Pursue This Opportunity?
Get AI-powered intelligence on this solicitation and the ones like it
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 750+ contractors already using CLEATUS
